BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, June 19, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

March 16, 2020

View Archived Issues

OyaGen to develop OYA-1 for the treatment of coronaviruses

Read More

Denali studies DNL-343 in healthy volunteers in new phase I trial

Read More

Researchers present phase II data for tafoxiparin in women in labor

Read More

Aclaris initiates phase IIa study of ATI-450 with methotrexate for moderate to severe RA

Read More

Chlorotoxin-CAR T cells specifically targeting glioblastomas shows preclinical antitumor activity

Read More

Poseida Therapeutics initiates phase I study of P-PSMA-101 CAR-T cells

Read More

Patient enrollment ongoing in phase I study of CS-3002

Read More

Phase IIb ARISE study of padsevonil does not reach statistical significance for primary endpoints

Read More

Anti-POTEF autoantibodies as new biomarker in primary ovarian insufficiency

Read More

NPSR1 as a novel nonhormonal target in endometriosis

Read More

First-in-human data for (R,R)-penehyclidine fumarate

Read More

New approach to cancer immunotherapy identified

Read More

FDA clears IND for phase I/II trial of Adaptive Phage Therapeutics' PhageBank

Read More

Researchers develop murine model of CMV infection in pregnancy

Read More

See in 3D

Read More

PharmaMar reports promising in vitro study results with Aplidin against coronavirus HCoV-229E

Read More

University of Edinburgh discloses new cyclophilin inhibitors

Read More

New glutaminyl cyclase inhibitors patented by Academia Sinica, NHRI

Read More

Daewoong Pharmaceutical describes dual BTK/ITK inhibitors

Read More

Merck KGaA discovers Bruton tyrosine kinase inhibitors

Read More

New pantetheinase inhibitors presented by Boehringer Ingelheim

Read More

Janssen collaborates with Beth Israel Deaconess on preventive vaccine candidate for COVID-19

Read More

Algernon to seek funding from COVID-19 Therapeutic Accelerator program for repurposed drug

Read More

Preclinical data show PAT-DX1 crosses blood-brain barrier via ENT2 pathway

Read More

Japanese approval for new Ozempic SD subcutaneous injection formulation

Read More

Kevzara enters global clinical program for use in severe COVID-19 infection

Read More

Trial of darunavir/cobicistat and hydroxychloroquine to reduce transmission of SARS-CoV-2 begins

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • Brain with puzzle piece removed

    Gene replacement rescues autism-related phenotypes in mice

    BioWorld Science
    Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
  • Red blood cells, DNA

    For clonal hematopoiesis, epigenetics can be in driver’s seat

    BioWorld Science
    Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
  • Illustration of amyloid plaques in Alzheimer's disease

    Elixiron’s enrupatinib shows upbeat interim phase II AD results

    BioWorld
    Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing